

For the Year Ended December 31, 2015

Introduction

This Management Discussion and Analysis ("MD&A") provides information that management believes is relevant to an assessment and understanding of the Company's consolidated results of operations and financial condition. This discussion should be read in conjunction with the Consolidated Financial Statements for the years ended December 31, 2015 and 2014 and the accompanying notes, which are prepared in accordance with International Financial Reporting Standards or "IFRS". This discussion is based on information available to management as of March 31, 2016, unless otherwise indicated.

Unless otherwise indicated, all dollar amounts are expressed in Canadian dollars.

The core business of the Company is to provide advanced technology biological filters for removal of odors, volatile organic compounds (VOCs) and hazardous air pollutants (HAPs) and for the conditioning of biogas renewable energy. With over 1,000 installed systems and over two decades of experience, the Company's groundbreaking biofilters are the technology of choice for wastewater treatment plants across North America and worldwide. Additional information about the Company, including our most recently filed Annual report, is available on SEDAR at www.sedar.com.

Forward Looking Statements

Certain statements in this report may contain "forward looking" statements that involve risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company or industry to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Words such as "may", "will", "expect", "believe", "plan", "intend", "should", "anticipate" and other similar terminology are used to identify forward looking statements. These statements reflect current assumptions and expectations regarding future events and operating performance and speak only as of the date of this MD&A. Forward looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly from the results discussed in the forward looking statements, including, but not limited to, the factors discussed under "Risks and Uncertainties". Although the forward looking statements contained in this MD&A are based upon what management of the Company believes are reasonable assumptions, the Company cannot assure investors that actual results will be consistent with these forward looking statements. These forward looking statements are made as of the date of this MD&A and the Company assumes no obligation, except as required by law, to update any forward looking statements to reflect new events or circumstances.

Non-IFRS Measures

“EBITDA,” “Adjusted EBITDA”, “Order Bookings,” “Order Backlog” and “Working capital” do not have any standardized meaning prescribed by IFRS and may not be comparable to measures presented by other companies.

EBITDA is used to denote earnings (loss) from operations before interest, income taxes, foreign exchange gains and losses, depreciation and amortization. Adjusted EBITDA, which includes additional adjustments for any gains or losses on re-measurements of debentures, should not be construed as a substitute for net earnings determined in accordance with IFRS. These measures are important to the Company since they are used by potential investors and lenders to evaluate the ongoing cash generating capability of the Company and thus the amounts they are willing to invest and lend to the Company. A reconciliation of Adjusted EBITDA to total Company earnings is contained in the MD&A when this measure is being used.

Order Bookings and Order Backlog are non-IFRS measures that the Company uses to evaluate its sales performance. Order Bookings are those binding contracts that the Company enters into during a fiscal year with a third party for the delivery of our products or services. As Order Bookings are received, the contract value (before any associated sales taxes) is included in the Order Backlog. The Order Backlog is reduced by the revenue that is recognized on each project and is also adjusted for foreign exchange changes.

Overview

Biorem is a leading clean technology company that designs, manufactures and distributes a comprehensive line of high-efficiency air emissions control systems used to eliminate odors, volatile organic compounds (VOCs) and hazardous air pollutants (HAPs). Biorem also offers Biogas Conditioning technologies specializing in biological treatment of hydrogen sulfide.

Biorem offers a selection of products that can be tailored to suit application specific requirements. Biorem ensures optimized long-term performance on every application by custom-designing their systems to meet the individual needs of their clients.

Biorem has sales and manufacturing offices across North America and in China, a dedicated research facility, an analytical and microbial laboratory, a worldwide sales representative network and a dedicated service and support division. As such, Biorem has the resources available to ensure that projects are handled promptly and professionally from conception to completion on a global basis.

The Company has more than 1,000 installed systems worldwide.

Significant Events for The Year

Key events of note in 2015 include the following;

- Order bookings during the year increased by 24% over the previous year to \$18.4 million.
- Order backlog at the end of the year increased by 19% to \$16.7 million from \$14.0 million at the end of 2014.
- Revenues increased 58% over 2014 to \$16.8 million for the year
- Gross profit grew 169% to \$3.8 million for the year
- The Company made long-term debt repayments of \$770,000.

Selected Annual Information

	2015	2014	2013
Revenue	\$16,880,000	\$10,683,000	\$19,596,000
Net earnings (loss)	1,688,851	(1,722,000)	718,000
Total Assets	9,295,000	7,689,000	8,910,000
Current portion LTD	2,874,000	2,424,000	3,548,000
Long-Term Debt (LTD)	-	1,109,000	-
Earnings(loss)per share			
- basic	\$0.13	\$(0.13)	\$0.06
- diluted	\$0.06	\$(0.13)	\$0.03

Operating Results

Revenue	2015	2014	Percent Change
	\$16,880,000	\$10,683,000	58%

Revenue by Geography

	2015	2014	2013
Canada	\$4,958,000	\$1,519,000	\$7,727,000
United States	6,160,000	6,316,000	7,402,000
China	2,665,000	938,000	977,000
Other international	3,097,000	1,910,000	3,490,000
Total Revenue	\$16,880,000	\$10,683,000	\$19,596,000

Biorem's core market is the North American municipal odour control market with international distribution established in China, Middle East, Americas and South Africa as well as opportunistically in other jurisdictions. Project delivery mix varies from period to period, however overall the Company relies heavily on the American and Canadian markets to generate revenue. The geographic mix in the current Order Backlog of the Company is consistent with the geographic mix for 2015 shown in the above table.

A number of factors contribute to variations in the Company's period over period results: customer scheduling and delivery of our products, the Company's mix of product and service offerings, the currency in which the revenue is earned and the timing of revenue recognition.

Revenue increased by 58% or \$6.2 million in 2015 over 2014 as a result of the larger Order Backlog at the beginning of the year and increased bookings during the year. At the beginning of 2014 the order backlog stood at \$10 million while the order backlog at January 1, 2015 was \$14 million. As well the decline in the Canadian dollar against the US dollar during 2015 had a positive impact on reported revenue, accounting for \$1.2 million of the increase over 2014 revenue. Fifty one percent of 2015 revenues came from ten customers while in 2014 nine customers accounted for 34% of total revenues.

Order Bookings	2015	2014	Percent Change
	\$18,400,000	\$14,795,000	24.4%

Order Bookings can vary considerably from period to period, due to both the size of the contracts won and the timing of the awarding of the contracts. Bookings in 2015 increased by over three million dollars from the Company's 2014 bookings. The increase in bookings largely came from Canada and China.

Order Backlog	2015	2014	Percent Change
	16,700,000	14,000,000	19.3%

The Company's Order Backlog at December 31, 2015 increased by \$2.7 million to \$16.7 million from the same measurement date a year ago. Order Backlog can vary significantly from period to period both due to the timing of the receipt of contracts and due to the completion date of the projects under contract. The increase in Order Backlog at December 31, 2015 is due to the increase in projects bid and won in 2015 and \$1.1 million is due to exchange gains on \$US denominated contracts. Due to customer scheduling, the Company cannot provide guidance as to the quarters when the Order Backlog will be converted into revenue. Management's current estimate is that the majority of the Order Backlog at December 31, 2015 will be realized as revenue by the end of fiscal 2016.

Gross Profit	2015	2014	Percent Change
	\$5,995,000	\$2,231,000	169%

Costs of goods sold is comprised of 2 main components; direct material costs that are in direct proportion to revenue recognized, and the cost of operations which includes engineering and project management costs that are relatively fixed.

Gross profit of \$6.0 million in 2015 was \$3.8 million more than the gross profit recorded in 2014. The increase in gross profit for the year was the result of the increase in project revenue for the year, an increase in the average gross margin percentage on projects completed and the impact of the change in the value of the Canadian dollar in 2015. The increase in dollar volume of projects completed in 2015 compared to 2014 accounted for \$1.6 million of the increase in gross profit in 2015. The decline of the Canadian dollar added \$463,000 and improved margins on contracts added a further \$850,000.

Gross profit in 2014 was negatively impacted by a one-time \$600,000 provision for loss that was recorded against a project that required remedial work. The amount of the provision for loss was based on management's estimate of the costs of the remedial work to be incurred. At December 31, 2015 management's estimate of the costs of remedial work required has not changed.

As a percentage of revenue, gross profit in 2015 was 35.5% compared to 20.9% in 2014. Gross profit before the fixed costs of engineering and project management as a percentage of revenue was 46% compared to 41% in 2014. Project management and engineering costs represented 11.5% of revenue in 2015 compared to 19.1% in 2014. The Company was able to reduce the cost of operations by \$125,000 in 2015 through staff reductions.

Adjusted EBITDA	2015	2014	Percent Change
	\$2,244,000	\$(916,000)	251%

Adjusted EBITDA increased by \$3.2 million in 2015 over 2014. The increase was the result of higher revenues and corresponding \$3.8 million increase in gross profit. The \$3.8 million increase in gross profit was partially offset by an increase in sales marketing costs of \$356,000 and an increase in general and administration expenses of \$106,000, a decrease of \$100,000 in research and development costs and a decrease in government assistance of \$60,000(see below for explanation of changes in sales and marketing, general and administration expenses and government assistance) A reconciliation of Adjusted EBITDA to net earnings (loss) is provided below.

Reconciliation of Adjusted EBITDA to net earnings (loss)

	2015	2014
Net earnings (loss)	\$1,689,000	\$(1,722,000)
Add (deduct)		
Depreciation and amortization	122,000	360,000
Loss (gain) on foreign exchange	(76,000)	(130,000)
Interest expense	509,000	576,000
Adjusted EBITDA	\$2,244,000	\$(916,000)

Sales and Marketing	2015	2014	Percent Change
	\$1,907,000	\$1,551,000	23.0%

The Company's sales and marketing expenses are composed of two significant categories; variable selling expenses and sales department expenses.

Variable selling costs represent commissions that are paid to both internal sales employees and external manufacturer representatives. These expenses are recognized over the course of the related contract. Sales Department expenditures relate primarily to departmental salaries and advertising expenses.

Total sales and marketing costs in 2015 were \$356,000 above the amount incurred in 2014 almost entirely due to the increased commission expense on the increased revenues in 2015. Commission expense in 2015 was \$1,035,000 versus \$800,000 in 2014. Travel and accommodation expenses were \$36,000 higher in 2015 than 2014.

Sales and marketing activities in fiscal 2015 were comparable to the activities conducted in 2014. Sales and marketing expenses in 2015 represented 11.3% of revenue compared to 14.5% in 2014. As a percentage of bookings, sales and marketing expense in 2015 were 10.4% compared to 10.5% in 2014.

Research and Development	2015	2014	Percent Change
	\$444,000	\$548,000	(19.0%)

Research and Development expenses include research and development salaries, material and laboratory costs as well as subcontractor costs for the development of and installation of demonstration sites.

R&D activities during 2015 were broad based and included continued development of advanced biofiltration media such as Nanosorbens with the start of field trials. These trials will be concluded in mid-2016 and if successful will be used to develop a commercialization strategy.

Work continued on an initiative to develop processes for biological treatment of contaminants in industrial exhausts at high temperatures. We continued to advance biotrickling filtration technology with special focus on high hydrogen sulfide concentrations and tropical climates. New media were developed and testing started. This program will be expanded in 2016 to position Biorem as a leader in this technology.

Other Income	2015	2014	Percent Change
	\$277,000	\$284,000	2.5%

Government Assistance is used to help fund the Company's Research and Development expenses. The Government Assistance relates to several programs which are offered by the Canadian Federal and Ontario Provincial governments. The assistance from these programs can fluctuate on a yearly basis depending on the activity that takes place during the year and the terms of the assistance programs.

The Company has been approved for funding through the Industrial Research Assistance Program (IRAP). The funding is to support the Company's research into advanced biological technologies for the control of odour and volatile organic compounds. The Company receives contributions of 50% of the eligible costs. The Company has recorded \$192,000 as other income during the year (2014 - \$101,000).

General and Administration	2015	2014	Percent Change
	\$1,798,000	\$1,692,000	6.3%

General and Administration expenses include administrative salaries, consulting, occupancy costs, office supplies, regulatory and transfer fees, travel and corporate affairs.

The \$106,000 increase in general and administration expenses in 2015 compared to 2014 was largely due to a \$250,000 increase in allowance for bad debts and \$75,000 related to the impact of the weaker Canadian dollar. These increases were offset by a \$200,000 reduction in depreciation and amortization of technology.

Summary of Quarterly Results

Thousands \$ Except share data	2015				2014			
	Q4	Q3	Q2	Q1	Q4	Q3	Q2	Q1
Revenue	3,311	4,171	4,709	4,689	3,968	2,282	2,459	1,974
Gross profit	1,300	1,508	1,656	1,531	1,326	521	55	329
Net earnings (loss)	125	318	718	528	(69)	(287)	(835)	(531)
EPS (loss) - basic	0.02	0.02	0.05	0.04	0.00	(0.03)	(0.06)	(0.04)
EPS (loss) - diluted	0.01	0.01	0.02	0.02	0.00	(0.03)	(0.06)	(0.04)

A number of factors contribute to variations in the Company's quarterly results: customer scheduling and delivery of our products and services, the Company's mix of product and service offerings, the currency in which the revenue is earned and the timing of revenue recognition.

Fourth Quarter 2015

Revenue in the fourth quarter of 2015 was \$3.3 million compared to \$4.2 million in the previous quarter and \$4.0 million in the fourth quarter of 2014. The decrease in fourth quarter 2015 revenue compared to the previous two quarters was attributable to the completion of a large project in the Company's third quarter. As well, deliveries for several projects were delayed into 2016 for reasons beyond Biorem's control.

The gross profit of \$1.3 million in the fourth quarter amounted to 39% of revenue, a decline from the previous quarter but in line with the gross profit margins achieved in 2014. The decline in margin in the fourth quarter was due to both a change in project mix and decreased sales revenue.

The fixed component of cost of goods sold which includes engineering and project management costs has averaged \$500,000 per quarter over the last four quarters, and was consistent in the fourth quarter.

With the exception of the variable portion of sales and marketing expenses, operating expenses for the quarter were in line with the previous quarters.

Liquidity

2015 Cash flow

Cash and cash equivalents	2015	2014	Percent Change
	\$2,725,000	\$1,212,000	124.8%

Cash and cash equivalents increased by \$1,513,000 to \$2.7 million as at December 31, 2015 from \$1.2 million as at December 31, 2014. Approximately 35% of the Company's cash is denominated in Canadian and 43% in US dollars as at December 31, 2015 compared to approximately 60% in US dollars at December 31, 2014. The decrease in percentage in US dollars held at December 31, 2015 compared to December 31, 2015 is due to the higher percentage of \$ Canadian denominated contracts completed in the latter half of 2015 compared to the prior year.

The change in cash for the year is due to net cash flows from operating, investing and financing activities as follows:

	2015	2014
Cash provided by (used in) operating activities	\$2,149,000	\$(445,000)
Cash provided by (used in) investing activities	-	(38,000)
Cash provided by (used in) financing activities	(787,000)	(219,000)
Foreign exchange gain(loss) on foreign cash	151,000	274,000
Net increase (decrease) in cash	\$1,513,000	\$(428,000)

Cash provided by (used in) operating activities – During 2015, operating activities before changes in non-cash operating working capital generated \$2,247,000 in cash compared to \$912,000 used in 2014. Changes in non-cash operating working capital used \$98,000 of cash compared to \$466,000 of cash provided in 2014. A reduction in restricted cash and accounts receivable provided \$605,000 of cash. A decrease in prepaid expenses and accounts payable contributed a further \$409,000 in cash from operating activities. These operating sources of cash were offset by cash used to fund an increase in unbilled revenue of \$698,000, and a decrease in unearned revenue of \$240,000.

Cash provided by (used in) investing activities - During 2015 the Company used \$6,000 to purchase equipment compared to \$30,000 used to purchase equipment in 2014.

Cash provided by (used in) financing activities - During the year the Company used \$770,000 to make principal payments and \$181,000 to pay interest on the 12.75% debentures, compared to \$219,000 of interest payments in 2014.

The Company received \$164,000 from the exercise of share purchase warrants and stock options.

Liquidity Risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they are due. The Board of Directors reviews and approves the Company's operating and capital budgets, as well as any material transactions out of the ordinary course of business including proposals on major investments. The Company manages liquidity risk by maintaining adequate capital, by continuously monitoring forecasts and actual cash flows and matching the maturity profiles of financial assets and liabilities.

The Company's objectives of managing liquidity risk are to forecast the liquidity position as accurately as possible and to maintain sufficient resources to pursue its growth strategy. The Company's liabilities include accounts payable and accrued liabilities, and unearned revenue as well as long and short term debt.

The Company's net current assets (liabilities) are summarized below.

	2015	2014
Cash	\$2,725,000	\$1,212,000
Restricted cash	715,000	1,005,000
Working capital	1,786,000	584,000
Current portion long term debt	2,874,000	2,424,000
Net current assets	\$1,786,000	\$584,000

At December 31, 2015, restricted cash includes \$500,000 in cash which has been deposited as collateral for a letter of credit issued to an insurance company under the terms of a performance bond. Restricted cash is not available for general use by the Company.

The Company is subject to a debt covenant in connection with its 12.75% debenture, as described in note 10 to the consolidated financial statements, which requires the Company to maintain an unrestricted cash balance of \$200,000 at the end of each quarter. Given this amount is required to be on hand and otherwise unencumbered at each reporting period, the Company has presented this amount within restricted cash.

The \$1,202,000 increase in working capital at December 31, 2015 compared to December 31, 2014 is primarily due to cash generated from operations in 2015.

In August of 2015 the holders of the series 1 convertible debentures agreed to extend the maturity date of these debentures to August 16, 2016. Management expects that the Company's long-term debt that is due in 2016 will be repaid from cash generated by operations and in the case of the 8% convertible debentures from the conversion of these debentures to common shares. However there is no certainty that cash generated from operations will be sufficient to repay the 12.75% debentures or that the convertible debentures will be converted to common shares.

A maturity analysis as at December 31, 2015 of the Company's financial liabilities based on gross, undiscounted cash flows is presented below. The maturity analysis is based on the earliest date that liabilities may be due.

	Carrying Amount	Contractual Cash Flow	Less than 1 month	1-3 months	3 months to 1 year	1+ years	Total
	\$	\$	\$	\$	\$	\$	\$
2015							
Accounts payable	1,794,540	1,794,540	1,794,540	-	-	-	1,794,540
Accrued liabilities	1,040,870	1,040,870	1,040,870	-	-	-	1,040,870
Current portion LTD	2,874,416	3,102,874	-	283,319	2,819,555	-	3,102,874
Long term debt	-	-	-	-	-	-	-
	5,709,826	5,938,284	2,835,410	283,319	2,819,555	-	5,938,284
2014							
Accounts payable	1,644,875	1,644,875	1,644,875	-	-	-	1,644,875
Accrued liabilities	1,078,963	1,078,963	1,078,963	-	-	-	1,078,963
Current portion LTD	2,423,827	2,541,842	-	252,029	2,289,813	-	2,541,842
Long term debt	1,109,363	1,489,152	-	-	89,280	1,399,872	1,489,152
	6,257,028	6,754,832	2,723,838	252,029	2,379,093	1,399,872	6,754,832

In the normal course of business, management will continue to look to other sources of funding including items such as project financing. Management is also continuing to improve the efficiency of all aspects of the Company's operations to ensure the most effective use of its' working capital. Through these activities, along with expected cash flow from operations, management believes that it will obtain adequate sources of funds to meet its liabilities as they come due, however there is no certainty that these strategies will be successful.

Capital Resources

The Company currently does not have any undrawn debt facilities. The Company does not have any significant capital expenditure projects underway or forecasted in 2016.

Financial instruments

At December 31, 2015 the Company held no forward exchange contracts. The Company plans to evaluate the use of forward exchange contracts in the future.

Commitments

Commitments include operating leases for office equipment and facilities, bank guarantees, and performance bonds issued by financial institutions in connection with facility leases and contracts with public sector customers. Aside from the aforementioned, the Company does not have any other business arrangements or any equity interests in unconsolidated companies that would have a significant effect on its assets and liabilities as at December 31, 2015.

Off-Balance Sheet Arrangements

As a general practice, the Company does not enter into off-balance sheet financing arrangements. Except for operating leases and letters of credit, all commitments are reflected on the balance sheet.

Transactions with Related Parties

The Company did not have any material related party transactions during the year ended December 31, 2015.

Outstanding Share Data

as at	March 30, 2016
Common shares	15,421,952
Employee stock options	447,000
Share purchase warrants	5,846,710
	21,715,662
Convertible debentures	16,633,115
Total	38,348,777

Significant Accounting Policies and Estimates

The preparation of the Company's consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related contingent assets and liabilities. On an on-going basis, management evaluates the estimates including those related to long-term revenue contracts, intangible assets, bad debts, warranty provisions and income taxes. The estimates are based on historical experience and on various other factors that are believed to be reasonable in the circumstances. Actual results may differ from these estimates. The following critical accounting policies include those which involve management's more significant judgments and estimates:

- a) Revenue recognition: The Company derives revenue from construction contracts which require performance over a time span which may extend beyond one or more accounting periods. The Company recognizes revenue on construction contracts using the percentage-of-completion method, based on costs incurred relative to the estimated total contract costs. Management has concluded that costs incurred are the best available measure of progress toward completion of these contracts. Estimated total direct contract

costs is subjective and requires the use of management's best judgments based upon the information available at that point in time. Management's estimate of total direct contract costs has a direct impact on the revenue recognized by the Company. Changes in estimates are reflected in the period in which they are made and would affect revenue and cost of sales and unbilled or unearned revenue.

The Company also provides for estimated losses on incomplete contracts in the period in which such losses are determined.

- b) **Deferred income taxes:** Deferred income tax assets are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment. The income tax bases of assets and liabilities are based upon the interpretation of income tax legislation across various jurisdictions. The deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing for reversal of temporary differences as well as possible audits of tax filings by the regulatory authorities. In accessing the realizability of deferred income tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax assets, projected future taxable income and tax planning strategies in making this assessment. The Company has not recorded deferred tax assets as at December 31, 2015.
- c) **Investment tax credits:** In the normal course of operations, the Company's Scientific Research & Experimental Development (SR&ED) expense claims are subject to review by federal and provincial government authorities. Reviews of certain of the Company's SR&ED claims are incomplete at December 31, 2015 and as such, amounts disclosed may be subject to change, pending the outcome of such reviews.
- d) **Warranty obligations:** Management routinely assesses and adjusts for its anticipated warranty costs based on experience and estimates of the potential warranty obligations for its installations.
- e) **Bad debt expense:** Management routinely reviews accounts receivable and sets up a reserve for bad debts on a customer-by-customer basis. This is an estimate since some of the reserved accounts may be collected and it may subsequently be found that some accounts currently deemed collectible become uncollectible.

- f) Long lived assets: Management reviews the carrying value of long lived assets including plant and equipment and amortizable intangible assets for impairment to determine if the carrying value of an asset may not be recoverable due to changes in the current and expected future use of the asset, external valuations of the asset, and the obsolescence or physical damage to the asset. If such indicators of impairment exist, the asset's recoverable amount is estimated. An impairment loss is recognized if the carrying amount of an asset or its related cash generating unit exceeds its estimated recoverable amount.
- g) Compound financial instruments: The financial liability component of a compound financial instrument is recognized initially at the fair value of a similar liability that does not have an equity conversion option. The equity component, representing the holders' option to convert into common shares, is recognized initially at fair value determined as the excess of the face value of the compound financial instrument and the fair value of the liability component. Any directly attributable transaction costs are allocated to the liability and equity components in proportion to their initial carrying amounts. Subsequent to initial recognition, the liability component of a compound financial instrument is measured at amortized cost using the effective interest method. The equity component of a compound financial instrument is included within contributed surplus and is not re-measured subsequent to initial recognition.

Interest, as well as any gains and losses relating to the financial liability are recognized in profit or loss.

Outlook

Order backlog is usually a good indicator of the Company's' revenue for the next twelve to eighteen months. Revenue can vary from quarter to quarter due to timing issues but generally revenues for a twelve month will be in the range of the backlog plus another 10-15% for orders booked and delivered in the same year. With a \$16.7 million order backlog at December 31, 2015 the Company expects 2016 revenues to be in line with those recorded in 2015. Bidding activity during the first two quarters of 2015 was strong but slackened during the third and fourth quarters. Bidding to date for the first quarter of 2016 has increased significantly and has already exceeded \$7 million.

Minimal changes to margins and operating costs are expected in 2016 compared to fiscal 2015.

The Company does not expect to benefit from changes in the value of the Canadian dollar vis a vis the US dollar in 2016 to the same extent that was realized in 2015.

New Business development initiatives in the America's; Africa; the Middle East and Asia, began in 2015 and continuing in 2016 are expected to result in increased bidding activity and orders from these markets in 2016.

The Company is also increasing its business development and product development activities in the renewable energy market and hopes to report positive results in this area in 2016.

Risks and Uncertainties

The Company is exposed to risks of varying degrees of significance which could affect its ability to achieve its objectives of profitability and growth. The principal risks to which the Company is described below.

Liquidity risk

At December 31, 2015 the Company had working capital of \$1,786,000, which is net of the \$2,874,000 current portion of the Company's long-term debt.

All of the Company's long-term debt is due between August and December 2016. Management expects that the long-term debt will be refinanced through cash generated from operations and the conversion of convertible debentures to common shares and other sources of financing. However there is no certainty that the convertible debentures will be converted to common shares or that cash flow from operations will be sufficient to make the principal and interest payments on the 12.75% debenture.

Sales Cycle

Our long sales cycle may cause revenue fluctuations period over period – since our operating expenses are largely based on anticipated revenue trends and a significant portion of our expenses are, and will continue to be, fixed, any delay in generating or recognizing revenues could negatively impact our business, operating results, financial condition or prospects.

Order Backlog

As of December 31, 2015 the Company's Order Backlog was \$16.7 million. However, the expected future revenue from the Company's Order Backlog may not be realized or, if realized, may not result in net earnings. Projects could remain in Order Backlog for an extended period of time. In addition, project cancellations or scope adjustments may occur from time to time with respect to contracts reflected in the Company's Order Backlog. Cancellation or delay of contracts may have a material adverse effect on our financial status.

Delays or Defaults in customer payments affecting liquidity

Due to the nature of our contracts, at times we commit resources to projects prior to receiving payments from our customers in amounts sufficient to cover expenditures as they are incurred. Delays in customer payments may require us to make a working capital investment. If a customer defaults in making payments on a project to which we have devoted significant resources, it could have a material negative effect on our liquidity as well as the results from operations.

Reputation

The Company's reputation for technical expertise, high level of service and the lower life cycle cost of products compared to our competitors' products is one of our most valuable business development assets. The loss of this reputation due to client dissatisfaction represents a risk to our ability to win additional business both from existing clients and from future clients.

Patents and Proprietary Right

The Company relies on a combination of patents, trademarks, trade secrets and knowledge to protect its proprietary technology and rights. There can be no assurance that the Company's patents will not be infringed upon, that the Company would have adequate remedies for any such infringement, or that its trade secrets will not otherwise become known or independently developed by its competitors. There can also be no assurance that any patents now or hereafter issued to, licensed by or applied for by the Company will be upheld, if challenged, or that the protections afforded thereby will not be circumvented by others.

Dependence on Subcontractors

The Company does not directly engage in field construction but relies on field construction subcontractors operating under the supervision of the Company's employees. The unavailability of field construction subcontractors or a substantial increase in pricing by a significant number of these subcontractors could adversely affect the Company. In addition, failure of subcontractors to properly perform work that has been subcontracted to them could adversely affect the Company by increasing the costs to the Company of completing a project and by damaging the Company's reputation.

Product Liability

If there are defects in our systems or if significant reliability, quality or performance problems develop with respect to our systems, there may be a number of negative effects on our business. The Company carries product liability insurance, which includes coverage for sudden or accidental pollution impact. It is possible that a customers' inability to comply with applicable pollution control laws or regulations stemming from failure or non-performance of the Company's products or systems may subject the Company to liability for any fines imposed upon such customer by regulatory authority or for damages asserted to have been incurred by any third party adversely affected.

The Company, along with multiple other defendants, is subject to Statement of Claim for \$12 million in damages related to an explosion that occurred at a water pollution control plant in Ontario in 2014. The Company believes the allegations against it in the statement of claim are without merit and plans to vigorously defend itself.

Competition

Virtually all contracts for the Company's products and services are obtained through competitive bidding. Although the Company competes on technical expertise, reputation for service and lower life cycle cost, there can be no assurance that the Company will maintain its competitive position in its principal markets.

Fixed Price Contracts may result in losses

The Company's receipt of a fixed price contract as a consequence of being the successful bidder carries the inherent risk that the Company's actual performance cost may exceed the estimates upon which its bid was based. To the extent that actual contract costs exceed estimated costs, the Company's profitability could be materially affected.

Foreign Exchange

The Company is subject to risk of exchange rate fluctuations related to anticipated revenues, Order Backlog and existing assets and liabilities denominated in currencies other than Canadian dollars. At December 31, 2015, the Company had US dollar denominated net monetary assets of \$2,258,000.

Stock Trading Volume is low

The monthly average trading volume of the BIOREM common shares on the Toronto Venture Exchange was 582,000 shares in 2015. Due to the low trading volume the price of the common shares could be subject to wide price fluctuations in response to business development announcements, competitors, quarterly variations in operating results, and other events or factors.

Risk to Product Development

Substantial corporate resources are currently being expended on the development of new media technologies. These technologies are constantly in development and have not yet been fully commercialized. There can be no guarantee that the new media technology will achieve the performance criteria which the Company believes is necessary for it to be a successful product in the market. In addition, there are risks associated with commercializing any product including the risk that full scale production may not be achieved at an acceptable cost. Failure to successfully commercialize the new media technologies may materially and adversely affect the Company's financial condition and results of operations.

Acceptance of new products by the Market

Market risk exists for new products such as the new media. There is no assurance that new products will be accepted by the market, that desired volumes will be realized over the product life or that the product life will not be shorter than expected due to product obsolescence. New products that are launched by the Company's competitors may also have price or other advantages over the Company's products. In addition, new product offerings may also require more significant marketing and sales efforts to gain market acceptance.

Dependency on key personnel

The success of the Company is dependent upon the attraction and retention of highly skilled personnel in a number of key areas including management positions. The unexpected loss or departure of any of the Company's key officers or employees could have a material adverse effect on the future operations of the Company. The success of the Company's business will depend, in part, upon the Company's ability to attract and retain qualified personnel as they are needed. There can be no assurance that the Company will be able to engage the services of such personnel or retain its current personnel.